Every year novel biologically active compounds are designed as antitumor agents. This
review covers and highlights some of the most important findings described during 2018 …

Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various
cancers. However, they have some limitations including poor selectivity and toxicity towards …

Sorafenib, a multiple kinase inhibitor, is widely used as a first-line treatment for
hepatocellular carcinoma. However, there is a need for more effective alternatives when …

Over the last few years, great emphasis has been given to develop ruthenium complexes to
act as target specified chemotherapeutic agents. Indeed, there are few reviews available …

Metal complexes in cancer therapy have attracted much interest mainly because metals
exhibit unique characteristics, such as redox activity, metal‐ligand interaction, structure and …

The reaction of the Ru (PPh3) 3Cl2 with HL1− 3− OH (− OH stands for the oxime hydroxyl
group; HL1− OH= diacetylmonoxime‐S‐benzyldithiocarbazonate; HL2− OH …

This review highlights the progress in the development of ruthenium (II)/(III) complexes with
flavone derivatives as potential therapeutic agents. We focused on natural hydroxyflavone …

To ascertain the bioinorganic chemistry of metals conjugated with quinones, the complexes
[Ag (ATV)(PPh3) 2](1),[Au (ATV)(PPh3)]· 2H2O (2), and [Cu (ATV)(PPh3) 2](3) were …

Twenty new zinc (II) complexes with 8-hydroxyquinoline (H-Q1–H-Q6) in the presence of 1,
10-phenanthroline derivatives (D1–D10) were synthesized and formulated as [Zn (Q1) 2 …

Three luminescent mixed ligand diorganotin (IV) complexes [Sn2Ph4 (L) 1–3 (DPA)(MeOH)
Cl](where L1=(Z)-N-((E)-3-ethoxy-2-hydroxybenzylidene) isonicotinohydrazonic acid, L2=(Z) …